NeoGenomics raises sales projections

FORT MYERS — NeoGenomics raised its revenue projections for the second quarter as it acquired more customers.

The cancer-testing company says it now expects second-quarter revenues of about $20 million to $20.5 million compared with the previous estimate of $18.8 million to $19.3 million. The better results represent a 30% year-over-year improvement.

“We experienced exceptionally strong year-over-year volume growth in April and May driven by a continued increase in the number of new customer accounts,” says Doug VanOort, the company's Chairman and CEO, in a statement. “The growth is geographically broad-based, and is being fueled by the increased size and productivity of our sales team and by new product activity.”